Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 randomized, double-blind, controlled study of linaprazan glurate in patients with Gastroesophageal reflux disease (GERD)

Next Previous
Trial Profile

A phase 3 randomized, double-blind, controlled study of linaprazan glurate in patients with Gastroesophageal reflux disease (GERD)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linaprazan-glurate (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Registrational; Therapeutic Use
  • Sponsors Cinclus Pharma

Most Recent Events

  • 24 Sep 2024 According to a Cinclus Pharma media release, planning to initiate the phase III program is underway, with an expected study start in 2025.
  • 23 Nov 2023 According to a Cinclus Pharma media release, the company expects to initiate this trial in 2024-2026.
  • 23 Nov 2023 According to a Cinclus Pharma media release, the company intends to recruit patients in the US, Europe and one additional region in 2024. The company plans to obtain market approval in 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top